personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: one year results from the GEFAL randomized trial

Session Details

Session Title: AMD I

Session Date/Time: Thursday 26/09/2013 | 08:30-10:30

Paper Time: 08:30

Venue: Hall 1 (Level 2)

First Author: L.Kodjikian FRANCE

Co Author(s):    E. Souied   G. Mimoun   M. Mauget-Faysse   E. Decullier     

Abstract Details


To demonstrate the non-inferiority in terms of clinical efficacy of bevacizumab versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration (AMD).


Multicenter French study involving 38 public and private-sector French ophthalmology centers.


GEFAL* is a non-inferiority head-to-head double-masked randomized clinical trial. Patients aged ≥ 50 years old were enrolled if they presented subfoveal neovascular AMD, with best-corrected visual acuity (BVCA) in the study eye of between 20/32 and 20/320 on the early treatment of diabetic retinopathy (ETDRS) chart, and a lesion area of less than 12 optic disk area. Patients were randomly assigned to one of the two study groups: intravitreal administration of bevacizumab (1.25 mg) or ranibizumab (0.50 mg). Hospital pharmacies were responsible for preparing, blinding and dispensing treatments. Patients were treated with a loading dose of 3 intravitreal injections during the first 3 months, followed by an as-needed regimen (one injection in case of active disease) for the remaining 9 months with monthly follow-up. The primary outcome was the change in visual acuity at one year. * “Groupe d’Etude Français Avastin versus Lucentis dans la DMLA néovasculaire” – French Study Group on Avastin versus Lucentis for neovascular AMD


501 patients have been included. The last patient-last visit occurred in November 2012. Statistical analyses are ongoing.


The GEFAL trial is a reliable double-masked study which respects the posology set out in the EMEA marketing authorization. GEFAL data will enhance the data currently available from head-to-head studies and may eventually help clinical decision-making for neovascular AMD.

Financial Disclosure:

The study was funded by the French grant scheme: “Programme Hospitalier de Recherche Clinique National 2008”. The French Ministry of Health financed the study and the French Health Insurance System financed the drugs.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy